US5583112A
(en)
*
|
1987-05-29 |
1996-12-10 |
Cambridge Biotech Corporation |
Saponin-antigen conjugates and the use thereof
|
NZ230747A
(en)
*
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
NL9002314A
(nl)
*
|
1990-10-23 |
1992-05-18 |
Nederlanden Staat |
Immunogene complexen, in het bijzonder iscoms.
|
GB9202933D0
(en)
*
|
1992-02-12 |
1992-03-25 |
Smithkline Beecham Biolog |
Vaccines
|
US5650398A
(en)
*
|
1992-07-02 |
1997-07-22 |
Cambridge Biotech Corporation |
Drug delivery enhancement via modified saponins
|
US5273965A
(en)
*
|
1992-07-02 |
1993-12-28 |
Cambridge Biotech Corporation |
Methods for enhancing drug delivery with modified saponins
|
NL9301690A
(nl)
*
|
1993-08-12 |
1995-04-18 |
Seed Capital Investments |
Verbindingen met adjuvans-activiteit.
|
WO1995009179A1
(fr)
*
|
1993-09-30 |
1995-04-06 |
Seed Capital Investments (Sci) B.V. |
Composes presentant une activite d'adjuvant
|
GB9326253D0
(en)
|
1993-12-23 |
1994-02-23 |
Smithkline Beecham Biolog |
Vaccines
|
US5597807A
(en)
*
|
1994-08-01 |
1997-01-28 |
University Of Saskatchewan |
Quinoa saponin compositions and methods of use
|
US5688772A
(en)
*
|
1994-08-01 |
1997-11-18 |
University Of Saskatchewan |
Quinoa saponin compositions and methods of use
|
AUPM873294A0
(en)
*
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
FR2762787B1
(fr)
*
|
1997-04-30 |
2000-10-06 |
Pasteur Merieux Serums Vacc |
Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
|
JP2002505665A
(ja)
*
|
1997-04-30 |
2002-02-19 |
メリュー・オラバックス |
Th1型アジュバントを含有する抗ヘリコバクターワクチン組成物
|
FR2762788B1
(fr)
*
|
1997-04-30 |
2000-10-06 |
Pasteur Merieux Serums Vacc |
Composition vaccinale anti-helicobacter pour usage par voie systemique sous-diaphragmatique
|
WO1998056415A1
(fr)
*
|
1997-06-11 |
1998-12-17 |
Aquila Biopharmaceuticals, Inc. |
Saponines purifiees servant d'adjuvants oraux
|
US6241995B1
(en)
|
1997-08-08 |
2001-06-05 |
University Of Saskatchewan |
Polygala senega compositions and methods of use
|
US6693087B1
(en)
|
1998-08-20 |
2004-02-17 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding POMP91A protein of Chlamydia
|
US6686339B1
(en)
|
1998-08-20 |
2004-02-03 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
|
AU5366099A
(en)
|
1998-08-20 |
2000-03-14 |
Connaught Laboratories Limited |
Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
|
ES2228497T3
(es)
|
1999-04-19 |
2005-04-16 |
Glaxosmithkline Biologicals S.A. |
Composicion adyuvante que comprende saponina y un oligonucleotido inmunoestimulante.
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
AU780444B2
(en)
|
1999-05-03 |
2005-03-24 |
Sanofi Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
EP1227837B1
(fr)
|
1999-10-22 |
2008-05-21 |
Aventis Pasteur Limited |
Procede visant a provoquer et/ou stimuler une reponse immunitaire aux antigenes tumoraux
|
EP1792995A3
(fr)
|
2000-05-08 |
2007-06-13 |
Sanofi Pasteur Limited |
Antigènes de chlamydia et fragments d'adn correspondants, et utilisations de ceux-ci
|
ES2276788T3
(es)
|
2000-05-10 |
2007-07-01 |
Sanofi Pasteur Limited |
Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones.
|
PT2266603E
(pt)
|
2000-10-18 |
2012-11-02 |
Glaxosmithkline Biolog Sa |
Vacinas tumorais
|
CA2438942A1
(fr)
|
2001-02-23 |
2002-09-26 |
Glaxosmithkline Biologicals S.A. |
Formulations d'un vaccin contre la grippe pour livraison intradermale
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
MY134424A
(en)
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
US20100221284A1
(en)
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
SE0202110D0
(sv)
|
2002-07-05 |
2002-07-05 |
Isconova Ab |
Iscom preparation and use thereof
|
EP1569515A4
(fr)
|
2002-10-23 |
2006-04-26 |
Glaxosmithkline Biolog Sa |
Methodes de vaccination contre le paludisme
|
SE0301998D0
(sv)
|
2003-07-07 |
2003-07-07 |
Isconova Ab |
Quil A fraction with low toxicity and use thereof
|
CA2565500A1
(fr)
|
2004-05-28 |
2005-12-15 |
Glaxosmithkline Biologicals S.A. |
Compositions de vaccin comprenant des virosomes et un adjuvant a base de saponine
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CN101107009B
(zh)
|
2005-01-20 |
2014-08-06 |
伊斯克诺瓦公司 |
包含纤连蛋白结合蛋白或纤连蛋白结合肽的疫苗组合物
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
PL1877426T3
(pl)
|
2005-04-29 |
2012-10-31 |
Glaxosmithkline Biologicals Sa |
Sposób profilaktyki lub leczenia zakażenia M. tuberculosis
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
EP1989308B1
(fr)
|
2006-03-03 |
2017-05-31 |
ProMIS Neurosciences Inc. |
Méthodes et compositions visant à traiter et à détecter des maladies induites par une sod1 à repliement incorrect
|
WO2008030154A1
(fr)
*
|
2006-09-08 |
2008-03-13 |
Hemocue Ab |
Agent d'hémolyse
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
EP2068918B1
(fr)
|
2006-09-26 |
2012-05-02 |
Infectious Disease Research Institute |
Composition de vaccin contenant un adjuvant synthetique
|
EA021391B1
(ru)
|
2007-03-02 |
2015-06-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор
|
BRPI0815199A2
(pt)
|
2007-08-13 |
2015-03-31 |
Glaxosmithkline Biolog Sa |
Uso de um antígeno derivado da proteína circunsporozóite de plasmodium falciparum
|
JP5501969B2
(ja)
|
2007-09-11 |
2014-05-28 |
ユニバーシティ オブ グェルフ |
クロストリジウム・ディフィシル由来の多糖免疫原
|
JP2011500730A
(ja)
|
2007-10-26 |
2011-01-06 |
ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント |
Tim−3を用いた治療および診断方法
|
EP2062594A1
(fr)
|
2007-11-21 |
2009-05-27 |
Wyeth Farma, S.A. |
Vaccin de la fièvre catarrhale du mouton et compositions immunogènes, procédé d'utilisation et son procédé de production
|
CN101952321B
(zh)
|
2007-12-24 |
2016-05-11 |
葛兰素史密斯克莱生物公司 |
重组rsv抗原
|
US8877208B2
(en)
|
2008-05-23 |
2014-11-04 |
The Regents Of The University Of Michigan |
Multivalent nanoemulsion vaccines
|
AU2009296458A1
(en)
|
2008-09-26 |
2010-04-01 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
WO2010094663A1
(fr)
|
2009-02-17 |
2010-08-26 |
Glaxosmithkline Biologicals S.A. |
Vaccin à virus inactivé contre la dengue, contenant un adjuvant sans aluminium
|
EP2437753B1
(fr)
|
2009-06-05 |
2016-08-31 |
Infectious Disease Research Institute |
Adjuvants lipidiques synthétiques à base de glucopyranosyle et compositions de vaccin les contenant
|
US20100316673A1
(en)
|
2009-06-16 |
2010-12-16 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
SG176807A1
(en)
|
2009-06-24 |
2012-01-30 |
Id Biomedical Corp Quebec |
Vaccine
|
DK2445526T3
(en)
|
2009-06-24 |
2016-06-27 |
Glaxosmithkline Biologicals Sa |
Recombinant RSV antigens.
|
EP3178490B1
(fr)
|
2009-07-15 |
2022-04-20 |
GlaxoSmithKline Biologicals S.A. |
Compositions à base de protéine f du vrs et procédés de fabrication associés
|
US20110110980A1
(en)
|
2009-09-02 |
2011-05-12 |
Wyeth Llc |
Heterlogous prime-boost immunization regimen
|
MY157607A
(en)
*
|
2009-09-10 |
2016-06-30 |
Merial Inc |
New vaccine formulations comprising saponin-containing adjuvants
|
WO2011034950A1
(fr)
|
2009-09-16 |
2011-03-24 |
Vaxart, Inc. |
Stratégie d'immunisation pour empêcher une infection par le h1n1
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
KR102143105B1
(ko)
|
2010-07-23 |
2020-08-11 |
이스코노바 에이비 |
인플루엔자 백신
|
MX354752B
(es)
|
2010-09-27 |
2018-03-20 |
Janssen Vaccines & Prevention Bv |
Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
|
KR20130140009A
(ko)
|
2010-10-15 |
2013-12-23 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
사이토메갈로바이러스 gb 항원
|
US9352030B2
(en)
|
2010-12-14 |
2016-05-31 |
Glaxosmithkline Biologicals, S.A. |
Mycobacterium antigenic composition
|
MD4177C1
(ro)
*
|
2011-01-14 |
2013-02-28 |
Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова |
Metodă de vaccinare contra hepatitei virale B a persoanelor imunocompromise
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
US9044420B2
(en)
|
2011-04-08 |
2015-06-02 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
DK2758432T3
(da)
|
2011-09-16 |
2019-06-03 |
Ucb Biopharma Sprl |
Neutraliserende antistoffer mod hovedtoksinerne TcdA og TcdB fra Clostridium difficile
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
CN108864291A
(zh)
|
2011-11-23 |
2018-11-23 |
拜奥文斯瑞有限公司 |
重组蛋白及其治疗用途
|
CA2856722C
(fr)
|
2011-11-30 |
2022-11-22 |
Emory University |
Inhibiteurs de jak antiviraux utiles dans le traitement ou la prevention d'infections retrovirales et autres infections virales
|
US11510875B2
(en)
|
2012-02-07 |
2022-11-29 |
Access To Advanced Health Institute |
Adjuvant formulations comprising TLR4 agonists and methods of using the same
|
EP3388835B1
(fr)
|
2012-05-16 |
2020-04-01 |
Immune Design Corp. |
Vaccins contre le hsv-2
|
EP2666785A1
(fr)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Vaccins basés sur la protéine complément C5a
|
WO2014024026A1
(fr)
|
2012-08-06 |
2014-02-13 |
Glaxosmithkline Biologicals S.A. |
Procédé pour éliciter une réponse immunitaire contre le vrs et b. pertussis chez les nourrissons
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
EP2703483A1
(fr)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
Vaccin à base de PCSK9
|
WO2014043189A1
(fr)
|
2012-09-14 |
2014-03-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Virus de l'herpès déficients pour la réplication conditionnelle et leur utilisation dans des vaccins
|
UY34506A
(es)
*
|
2012-12-10 |
2014-06-30 |
Fernando Amaury Ferreira Chiesa |
Adyuvante de vacunación, preparación y vacunas que lo contienen
|
WO2014140894A2
(fr)
|
2013-03-15 |
2014-09-18 |
Bioven 3 Limited |
Protéines de synthèse à auto-assemblage
|
ES2924914T3
(es)
|
2013-03-15 |
2022-10-11 |
Glaxosmithkline Biologicals Sa |
Vacuna contra rinovirus humano
|
AR095962A1
(es)
|
2013-04-01 |
2015-11-25 |
Moreinx Ab |
Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
|
US8957047B2
(en)
|
2013-04-18 |
2015-02-17 |
Immune Design Corp. |
GLA monotherapy for use in cancer treatment
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
EP3030260A1
(fr)
|
2013-08-05 |
2016-06-15 |
GlaxoSmithKline Biologicals S.A. |
Compositions immunogènes en combinaison
|
JP6306700B2
(ja)
|
2013-11-01 |
2018-04-04 |
ユニバーシティ オブ オスロUniversity of Oslo |
アルブミン改変体及びその使用
|
WO2015071763A2
(fr)
|
2013-11-15 |
2015-05-21 |
Oslo Universitetssykehus Hf |
Epitopes peptidiques de lymphocytes t cytotoxiques et lymphocytes t specifiques a l'antigene, procede pour leur decouverte, et leurs utilisations
|
WO2015092710A1
(fr)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Administration simultanée controlatérale de vaccins
|
AU2014373928C1
(en)
|
2013-12-31 |
2020-12-17 |
Access To Advanced Health Institute |
Single vial vaccine formulations
|
EP3107568B1
(fr)
|
2014-02-20 |
2024-03-27 |
Vaxart, Inc. |
Formulations pour administration dans l'intestin grêle
|
JP6664338B2
(ja)
|
2014-06-13 |
2020-03-13 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組合せ物
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
WO2016011386A1
(fr)
|
2014-07-18 |
2016-01-21 |
University Of Washington |
Compositions de vaccin anticancéreux et leurs méthodes d'utilisation
|
US11083788B2
(en)
|
2014-10-10 |
2021-08-10 |
The Regents Of The University Of Michigan |
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
|
AR102548A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
|
MA40920A
(fr)
|
2014-11-07 |
2017-09-12 |
Takeda Vaccines Inc |
Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
|
CA2977493C
(fr)
|
2015-03-03 |
2023-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Plateforme d'affichage provenant de proteines d'enveloppe de spores bacteriennes
|
US10647964B2
(en)
|
2015-03-05 |
2020-05-12 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
CA2988761A1
(fr)
|
2015-06-12 |
2016-12-15 |
Vaxart, Inc. |
Formulations pour l'administration dans l'intestin grele d'antigenes du rsv et des norovirus
|
IL257800B2
(en)
|
2015-09-03 |
2023-11-01 |
Novavax Inc |
Immune compositions with improved stability and immunogenicity
|
EP3138579A1
(fr)
|
2015-09-05 |
2017-03-08 |
Biomay Ag |
Protéine de fusion pour son utilisation dans le traitement d'une infection par le virus de l'hépatite b
|
CA3004498A1
(fr)
|
2015-11-09 |
2017-05-18 |
Neil R. Cashman |
Epitopes de la beta-amyloide et anticorps associes
|
CA3004482A1
(fr)
|
2015-11-09 |
2017-05-18 |
Neil R. Cashman |
Epitopes n-terminaux dans la beta-amyloide et anticorps conformationnellement selectifs associes
|
CN108350052A
(zh)
|
2015-11-09 |
2018-07-31 |
英属哥伦比亚大学 |
淀粉样蛋白β中间区域中的表位及其构象选择性抗体
|
WO2017158421A1
(fr)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Immunoglobulines anti-virales synthétiques
|
KR20180127320A
(ko)
|
2016-03-14 |
2018-11-28 |
유니버시티에트 이 오슬로 |
변경된 FcRn 결합을 갖는 조작된 면역글로불린
|
US11173207B2
(en)
|
2016-05-19 |
2021-11-16 |
The Regents Of The University Of Michigan |
Adjuvant compositions
|
EP3471761A2
(fr)
|
2016-06-21 |
2019-04-24 |
University Of Oslo |
Fragments de vaccin de liaison à hla et leurs utilisations
|
WO2018037045A1
(fr)
|
2016-08-23 |
2018-03-01 |
Glaxosmithkline Biologicals Sa |
Peptides de fusion avec des antigènes liés à des fragments courts de chaîne invariante (cd74)
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
EP3295956A1
(fr)
|
2016-09-20 |
2018-03-21 |
Biomay Ag |
Construction de polypeptide comprenant des fragments d'allergenes
|
US11466292B2
(en)
|
2016-09-29 |
2022-10-11 |
Glaxosmithkline Biologicals Sa |
Compositions and methods of treatment
|
US20180125920A1
(en)
|
2016-11-09 |
2018-05-10 |
The University Of British Columbia |
Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
|
WO2018096396A1
(fr)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Variants d'albumine et leurs utilisations
|
US10695424B2
(en)
|
2016-12-07 |
2020-06-30 |
Glaxosmithkline Biologicals S.A. |
Method of making a liposome composition
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
EP3554538A2
(fr)
|
2016-12-16 |
2019-10-23 |
Institute for Research in Biomedicine |
Nouvelles protéines f du vrs de pré-fusion recombinant et leurs utilisations
|
GB201621686D0
(en)
|
2016-12-20 |
2017-02-01 |
Glaxosmithkline Biologicals Sa |
Novel methods for inducing an immune response
|
CA3066020A1
(fr)
|
2017-06-16 |
2018-12-20 |
Glaxosmithkline Biologicals Sa |
Methode de traitement
|
AU2018304957A1
(en)
|
2017-07-18 |
2020-02-13 |
In3Bio Ltd |
Synthetic proteins and therapeutic uses thereof
|
US20210069319A1
(en)
|
2017-09-07 |
2021-03-11 |
University Of Oslo |
Vaccine molecules
|
US20220118076A1
(en)
|
2017-09-07 |
2022-04-21 |
University Of Oslo |
Vaccine molecules
|
AU2018330165A1
(en)
|
2017-09-08 |
2020-04-02 |
Access To Advanced Health Institute |
Liposomal formulations comprising saponin and methods of use
|
JP2020533354A
(ja)
|
2017-09-13 |
2020-11-19 |
サノフィ・パスツールSanofi Pasteur |
ヒトサイトメガロウイルス免疫原性組成物
|
AU2018359558C1
(en)
|
2017-11-03 |
2022-09-22 |
Takeda Vaccines, Inc. |
Method for inactivating Zika virus and for determining the completeness of inactivation
|
BR112020010635A2
(pt)
|
2017-12-01 |
2020-11-10 |
Glaxosmithkline Biologicals S.A. |
extração de saponina
|
EP3717001A1
(fr)
|
2017-12-01 |
2020-10-07 |
GlaxoSmithKline Biologicals S.A. |
Purification de saponine
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
IL305911A
(en)
|
2018-03-19 |
2023-11-01 |
Novavax Inc |
Multifunctional nanoparticle vaccines for influenza
|
EP3569612A1
(fr)
|
2018-05-18 |
2019-11-20 |
Biomay Ag |
Traitement et prévention d'allergies aux acariens
|
CN112638936A
(zh)
|
2018-06-12 |
2021-04-09 |
葛兰素史密丝克莱恩生物有限公司 |
腺病毒多核苷酸和多肽
|
EP3581201A1
(fr)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 polypeptides et leurs utilisations
|
MX2021001479A
(es)
|
2018-08-07 |
2021-04-28 |
Glaxosmithkline Biologicals Sa |
Novedosos procesos y vacunas.
|
US11547672B2
(en)
|
2018-09-14 |
2023-01-10 |
Massachusetts Institute Of Technology |
Nanoparticle vaccine adjuvant and methods of use thereof
|
WO2020128012A1
(fr)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Méthodes d'induction d'une réponse immunitaire
|
JP2022524007A
(ja)
|
2019-03-05 |
2022-04-27 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
B型肝炎免疫化レジメンおよび組成物
|
IT201900007060A1
(it)
|
2019-05-21 |
2020-11-21 |
St Superiore Di Sanita |
Cellule tumorali ingegnerizzate e loro usi
|
KR20220125149A
(ko)
|
2019-05-25 |
2022-09-14 |
액세스 투 어드밴스드 헬스 인스티튜트 |
애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법
|
JP2022539067A
(ja)
|
2019-06-25 |
2022-09-07 |
イン3バイオ・リミテッド |
安定化キメラ合成タンパク質及びその治療的使用
|
IT201900012540A1
(it)
|
2019-07-22 |
2021-01-22 |
Humanitas Mirasole Spa |
Inibitori di CHI3L1 e loro usi
|
US20230201334A1
(en)
|
2019-07-24 |
2023-06-29 |
Glaxosmithkline Biologicals Sa |
Modified human cytomegalovirus proteins
|
WO2021097347A1
(fr)
|
2019-11-15 |
2021-05-20 |
Infectious Disease Research Institute |
Agoniste de rig-i et formulation d'adjuvant pour le traitement de tumeurs
|
US10953089B1
(en)
|
2020-01-27 |
2021-03-23 |
Novavax, Inc. |
Coronavirus vaccine formulations
|
EP4255919A2
(fr)
|
2020-12-02 |
2023-10-11 |
GlaxoSmithKline Biologicals S.A. |
Nouveaux antigènes
|
CN117320745A
(zh)
|
2021-03-30 |
2023-12-29 |
维拉瓦克斯股份公司 |
Sars-cov-2亚单位疫苗
|
EP4313132A1
(fr)
|
2021-03-31 |
2024-02-07 |
Vib Vzw |
Compositions de vaccin pour trypanosomatides
|
WO2023046898A1
(fr)
|
2021-09-23 |
2023-03-30 |
Viravaxx AG |
Vaccin contre le virus de l'hépatite b induisant la production d'anticorps neutralisants spécifiques de pres
|
WO2023114727A1
(fr)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Système de vaccin du bactériophage lambda
|
US20230190920A1
(en)
|
2021-12-19 |
2023-06-22 |
Massachusetts Institute Of Technology |
Compositions and methods for long-lasting germinal center responses to a priming immunization
|
WO2023144665A1
(fr)
|
2022-01-28 |
2023-08-03 |
Glaxosmithkline Biologicals Sa |
Protéines de cytomégalovirus humain modifiées
|